SCHEMBL3589134

SCHEMBL3589134

COC(=O)CCCCC(CCc1ccccc1O[Si](C)(C)C(C)(C)C)Oc1ccc(C(=O)OC)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PPARD Q03181 1/20 0.34
MAPT P10636 5/20 0.34
RAB9A P51151 2/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PPARA Q07869 1/20 0.34
KDM4E B2RXH2 2/20 0.33
POLB P06746 1/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
VDR P11473 1/20 0.33
HSD17B10 Q99714 1/20 0.32
NPC1 O15118 1/20 0.32
FAAH O00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13443503 0.85 PPARD (0.44) PPARGTDP1L3MBTL1PPARDMAPT
SCHEMBL3591129 0.83 MAPT (0.39) PPARGTDP1L3MBTL1MAPTRAB9A
SCHEMBL6002376 0.82 NPSR1 (0.44) NPSR1TDP1L3MBTL1MAPTRAB9A
SCHEMBL6001865 0.81 PPARG (0.43) PPARGTDP1L3MBTL1PPARDMAPT
SCHEMBL3600337 0.80 PPARG (0.43) PPARGL3MBTL1PPARDLMNAPPARA
SCHEMBL13443505 0.78 L3MBTL1 (0.47) L3MBTL1KDM4EALDH1A1GAA
SCHEMBL13443507 0.78 KEAP1 (0.44) TDP1MAPTLMNAKDM4EALDH1A1
SCHEMBL13443506 0.78 L3MBTL1 (0.46) L3MBTL1MAPTKDM4EALDH1A1GAA
SCHEMBL13443487 0.78 PPARG (0.40) PPARGTDP1L3MBTL1PPARDMAPT
SCHEMBL3602387 0.75 MAPT (0.37) TDP1L3MBTL1MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
EP-1216223-B1 NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES BAYER HEALTHCARE AG (DE) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties PC, GOT2, SDHA PPARG 206/4885NPSR1 3078/4885TDP1 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.